A Phase 1, Open-Label Study in Healthy Subjects to Evaluate the Absolute Bioavailability of AG-221 by a Microtracer Approach.
Xiaomin WangJian ChenJosephine ReyesSimon ZhouMaria PalmisanoYan LiPublished in: Oncology and therapy (2019)
Celgene Corporation.